Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity.
Open accessThe DOI matches its Crossref record; 105 of the 124 references it cites were found in a registry or an index.
Abstract
Camptothecins are broad-spectrum anticancer drugs that specifically target DNA topoisomerase I (Topo I). The formation of a cleavable drug-Topo I-DNA complex results in lethal double-strand DNA breakage and cell death. However, de novo or acquired clinical resistance to camptothecins is common. Studies of the camptothecin analog irinotecan suggest the following general mechanisms of resistance: (i) variable levels of the enzymes involved in the conversion of irinotecan; (ii) reduced cellular accumulation from active drug efflux; (iii) reduced levels of Topo I expression; (iv) alterations in the structure of Topo I from different mutations; (v) alterations in the cellular response to camptothecin-Topo I-DNA complex formation, which involves proteasome degradation of Topo I and/or enhanced DNA repair; and (vi) activation of the transcription factor nuclear factor kappa B by DNA damage and subsequent suppression of apoptosis. Multiple approaches using pharmacological and biological modulation to circumvent the above mechanisms of resistance have been incorporated into ongoing clinical trials and are expected to enhance the antitumor activity of irinotecan and reduce its systemic toxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Carboxylesterase 2 (CES2) is the critical enzyme for the activation of irinotecan, which can catalyze the conversion of irinotecan to the more active form of SN-38 (a topoisomerase inhibitor) [88].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [88]
In the citing paper
“In addition, the amount of TOP-1 bound to DNA is reduced, which may also lead to CRC resistance to irinotecan [88,131].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [88]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
THE NF-κB AND IκB PROTEINS: New Discoveries and Insights
Baldwin, A. S. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.649 · Cited by 4,979
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256 · cited 1×
“Initial approval in the United States was as a second-line treatment for metastatic colorectal cancer, after failure of 5-fluorouracil (5-FU) and leucovorin [2], and more recently it has been approved for use in combination with 5-FU/leucovorin as a first-line treatment for this disease [3, 4].”
BackgroundAn Essential Role for NF-κB in Preventing TNF-α-Induced Cell Death
Beg, A. A., & Baltimore, D. (1996) · Science · doi:10.1126/science.274.5288.782 · Cited by 3,047
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431302 · Cited by 3,005
The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous Polyposis
Steinbach, G., Lynch, P. M., Phillips, R. K. S., Wallace, M. H., Hawk, E., Gordon, G. B., Wakabayashi, N., Saunders, B., Shen, Y., Fujimura, T., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006293422603 · Cited by 2,526
Palombella, V. J., Rando, O. J., Goldberg, A. L., & Maniatis, T. (1994) · Cell · doi:10.1016/s0092-8674(94)90482-0 · Cited by 2,096
Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB
Baldwin, A. S. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11991 · Cited by 1,434
Noda, K., Nishiwaki, Y., Kawahara, M., Negoro, S., Sugiura, T., Yokoyama, A., Fukuoka, M., Mori, K., Watanabe, K., Tamura, T., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa003034 · Cited by 1,371
Cunningham, D., Pyrhönen, S., James, R. D., Punt, C. J., Hickish, T. F., Heikkila, R., Johannesen, T. B., Starkhammar, H., Topham, C. A., Awad, L., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)02309-5 · Cited by 1,259
Moreira, A. L., Sampaio, E. P., Zmuidzinas, A., Frindt, P., Smith, K. A., & Kaplan, G. (1993) · The Journal of experimental medicine · doi:10.1084/jem.177.6.1675 · Cited by 1,045
Research works printed but not linked: 8
- Ilson D, Enzinger P, Saltz L et al. Phase II trial of weekly irinotecan + cisplatin in advanced gastric cancer. Proc Am Soc Clin Oncol 1999; 18: 259a (Abstr).
- Hecht JR. Gastrointestinal toxicity of irinotecan. Oncology 1998; 12: 72-78.
- Prados M, Kuhn J, Yung W et al. A phase-I study of CPT-11 given every 3 weeks to patients with recurrent malignant glioma. A North American Brain Tumor Consortium (NABTC) study. Proc Am Soc Clin Oncol 2001; 19: 162 (Abstr 627).
- Kameyama M, Shoichi I, Ohtsuka K et al. Activation and detoxifica- tion of CPT-11 by human lung cancer cells. Proc Am Soc Clin Oncol 2000; 19: 505a (Abstr 1975).
- Villalona-Calero MA, Kuhn JG, Drengler R et al. Pharmaco- logically-based phase I study of mitomycin C (MMC) as a modulator of irinotecan (CPT-11) antitumor activity. Proc Am Soc Clin Oncol 2001; 20: 101a (Abstr 400).
- Kolesar J, Miller J, Duan W, Villalona-Calero M. TI induction in PBMC by mitomycin-C predicts irinotecan response. Proc Am Soc Clin Oncol 2002; 21: 115 (Abstr 456).
- Ratain, 1999, A phase I study of irinotecan (CPT-11) with pharmacokinetic modulation by cyclosporine A (CSA) and phenobarbital (PB), Proc Am Soc Clin Oncol, 18, 202a
- Takeda, 2001, Prevention of irinotecan (CPT-11)-induced diarrhea by oral alkalization combined with control of defecation in cancer patients, Int J Cancer, 92, 269, 10.1002/1097-0215(200102)9999:9999<::AID-IJC1179>3.0.CO;2-3 · DOI · Paper page
Cited by
Items 301–400 of 419
Wang, Y., Sun, X.-Y., Ma, F., Ren, M., Zhao, R., Qin, M., Zhu, X.-H., Xu, Y., Cao, N.-D., Chen, Y.-Y., et al. (2025) · Journal of Chinese Integrative Medicine · doi:10.1016/j.joim.2025.04.006 · Cited by 4
Self-citationLi, J., Miao, P., Guan, X., Gao, F., Khan, A. J., Wang, T., & Zhang, F. (2021) · Journal of Macromolecular Science Part B · doi:10.1080/00222348.2021.1945080 · Cited by 4
Aoullay, Z., Smith, A., Slaoui, M., Bouchikhi, I. E., Ghazal, H., Idrissi, N. A., Meddah, B., Lynch, K. L., Cherrah, Y., & Wu, A. H. B. (2023) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2022.0109 · Cited by 4
Chiu, P.-F., Chang, C., Huang, P.-S., Lin, Y., Lin, C.-S., Yang, H., Hsu, L., Yu, L. C., & Liang, P. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00476 · Cited by 4
Pahade, P., Pradhan, L. P., Chowdhury, S., Bose, D., Durgbanshi, A., Carda‐Broch, S., & Péris-Vicente, J. (2024) · Microchemical Journal · doi:10.1016/j.microc.2024.112349 · Cited by 4
Hronek, J., & Reed, M. (2015) · Clinical journal of oncology nursing · doi:10.1188/15.cjon.751-757 · Cited by 5
Breuillard, C., Moinard, C., Goron, A., Neveux, N., Reviers, A. D., Mazurak, V. C., Cynober, L., & Baracos, V. E. (2021) · Clinical Nutrition · doi:10.1016/j.clnu.2021.05.035 · Cited by 5
Jabbar, A., & Kathem, S. H. (2019) · Iraqi Journal of Pharmaceutical Sciences · doi:10.31351/vol28iss1pp37-43 · Cited by 4
Hebbar, M., Fournier, P., & ROMANO, O. (2009) · European Journal of Cancer Care · doi:10.1111/j.1365-2354.2009.01134.x · Cited by 4
DRUGS USED IN CANCER CHEMOTHERAPY
(2010) · Elsevier eBooks · doi:10.1016/b978-0-444-53267-1.50004-6 · Cited by 4
Hennig, L., Monecke, A., Hoang, N. A., Thieme, R., Prill, S., Hoffmeister, A., Tuennemann, J., Bechmann, I., Lordick, F., & Kallendrusch, S. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01694-z · Cited by 3
Functional roles and regulatory mechanisms of paeonol in the treatment of liver disease
Shu, M. Z., Fang, M., Xu, T., & Yan, Q. (2026) · Natural Products and Bioprospecting · doi:10.1007/s13659-025-00554-3 · Cited by 3
Li, Z., Peng, Y., Wang, Q., Zhou, H., & Fu, X. (2026) · ACS Nano Medicine · doi:10.1021/acsnanomed.5c00190 · Cited by 7
Resistance Mechanisms to Colorectal Cancer Therapeutics and the Clinical Implications
Emmerich, P. B., Clipson, L. J., & Deming, D. A. (2017) · Current Colorectal Cancer Reports · doi:10.1007/s11888-017-0374-5 · Cited by 3
Cetuximab directly inhibits P-glycoprotein function in vitro independently of EGFR binding
Chu, C., Noël‐Hudson, M., Bénard, J., Ha‐Duong, T., Allaoui, F., Farinotti, R., & Bonhomme‐Faivre, L. (2015) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2015.04.014 · Cited by 4
Upadhyay, S. K., Rai, R. C., Gehtori, R., Paliwal, A., Gautam, P., & Joshi, P. (2017) · Springer eBooks · doi:10.1007/978-3-319-48683-3_20 · Cited by 4
Zhang, W., Su, S., & Yang, P. (2025) · Chinese Journal of Organic Chemistry · doi:10.6023/cjoc202407038 · Cited by 2
Zhao, Z., Wang, H., Tian, N., Yan, H., & Wang, J. (2021) · Archiv der Pharmazie · doi:10.1002/ardp.202100213 · Cited by 2
Chemoresistance Mechanisms in Colon Cancer: Focus on Conventional Chemotherapy
Mladenić, K., & Sedić, M. (2021) · Clinical Cancer Drugs · doi:10.2174/2212697x08666211206102503 · Cited by 2
Franco, C. C., Mitxelena‐Iribarren, O., Calero-Castro, F. J., Astigarraga, M., Tuñón, J. M. C., Laga, I., Pereira, S., Arana, S., Mujika, M., & Ruiz, F. J. P. (2023) · Bioengineering · doi:10.3390/bioengineering10020183 · Cited by 2
Calheiros, J., Raimundo, L., Morais, J., Matos, A. C., Minuzzo, S. A., Indraccolo, S., Sousa, E., Correia‐da‐Silva, M., & Saraiva, L. (2023) · Cancers · doi:10.3390/cancers15245718 · Cited by 2
Pacheco-Barcía, V., Méndez, A. M., Hernández-Jiménez, E., Jiménez‐Fonseca, P., Martín, A. J. M., Custodio‐Cabello, S., Palka-Kotlowska, M., Gonzalez-Diaz, I., & Cabezón‐Gutiérrez, L. (2025) · World Journal of Clinical Oncology · doi:10.5306/wjco.v16.i10.107877 · Cited by 1
Hazar, M., Başaran, N., & DİLSİZ, S. A. (2026) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.70683 · Cited by 2
Hao, C., Chen, L., Liao, F., Chen, L., Yao, Y., & Song, Q. (2026) · Translational Oncology · doi:10.1016/j.tranon.2026.102701 · Cited by 1
Canhão, P. G. M., Smeuninx, A., Geerinckx, S., Evers, R., Snoeys, J., Augustijns, P., & Kourula, S. (2026) · Toxicology in Vitro · doi:10.1016/j.tiv.2026.106221 · Cited by 1
Dong, T., Xu, J., Wang, X., Sun, Z., Wang, S., Fanghui, C., Zhu, H., Zhang, X., Xu, S. X., Zheng, C., et al. (2026) · Pharmaceuticals · doi:10.3390/ph19030515 · Cited by 1
Two Worlds, One Battle: How Bacteria and Malignancies Converge on Drug Resistance
Papaneophytou, C. P. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27104239 · Cited by 2
Li, G. L., Qu, H., Wang, Y., Periyasami, G., Luan, H., Noruzi, E. B., Zhang, H., Ma, C., Lu, Z., Su, C., et al. (2026) · ACS Sensors · doi:10.1021/acssensors.6c00718 · Cited by 1
Ohmori, K., & Fukuda, K. (2014) · Cited by 1
Robins, I. (2017) · Journal of Neurology and Neuromedicine · doi:10.29245/2572.942x/2017/2.1109 · Cited by 1
Cancer biology and other disorders: beneficial role of camptothecin and novel derivatives
Raghavendra, P. B. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-820499-3.00001-x · Cited by 1
(2015) · Elsevier eBooks · doi:10.1016/b978-0-444-53717-1.01572-9 · Cited by 1
Advances in systemic chemotherapy and immunotherapy for metastatic colorectal cancer
Grandhi, N., Patel, B. G., & Aranha, O. (2023) · Seminars in Colon and Rectal Surgery · doi:10.1016/j.scrs.2023.100972 · Cited by 1
Diversity of oncopharmacogenetic profile within Spanish population
Ferrer‐Bolufer, I., Galiana-Vallés, X., Álvarez, S. I., Mira, A. S., Luján, C. G., Aguilera, M. J. S., González‐Tarancón, R., Naranjo, M. B., Salas, P. C., González, M. S., et al. (2024) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000530 · Cited by 1
Assembly of Glycopeptides in Living Cells Resembling Viral Infection for Cargo Delivery
Tian, F., Guo, R., Wu, C., Liu, X., Zhang, Z., Wang, Y., Wang, H., Li, G., & Yu, Z. (2024) · Angewandte Chemie · doi:10.1002/ange.202404703 · Cited by 2
Development of resistance to anticancer medications: Challenges and clinical implications
D’Souza, M. S., Hussain, A. R., Krmic, M., Niha, A., & Ray, S. D. (2024) · Side effects of drugs annual · doi:10.1016/bs.seda.2024.10.004 · Cited by 2
Rejili, M., Farahani, N., Alimohammadi, M., & Hushmandi, K. (2026) · Discover Oncology · doi:10.1007/s12672-026-05260-1 · Cited by 3
Zhu, Z. (2007) · Elsevier eBooks · doi:10.1016/b978-012369393-8/50004-3 · Cited by 2
Harr, M. W., & Willey, J. C. (2007) · International Journal of Oncology · doi:10.3892/ijo.30.6.1553 · Cited by 1
Natural and Acquired Resistance to Cancer Therapies
Sikic, B. I. (2008) · Elsevier eBooks · doi:10.1016/b978-141603703-3.10049-4 · Cited by 3
Sangpheak, K. (2018) · Chula Digiverse · doi:10.58837/chula.the.2018.35 · Cited by 1
Sinha, B. K. (2023) · Preprints.org · doi:10.20944/preprints202312.1293.v1
Aguilar, E. H. (2011) · Gredos (University of Salamanca) · doi:10.14201/gredos.108984 · Cited by 2
Drug resistance to topoisomerase directed chemotherapy in human multiple myeloma
Turner, J. G. (2008) · Digital Commons - University of South Florida (University of South Florida)
Drug resistance mechanisms in a high grade glioma cell line
Al-Ghafari, A. B. (2013) · Nottingham ePrints (University of Nottingham)
Clinical resistance to platinum chemotherapy in ovarian cancer
Newton, C. L. (2009) · OpenGrey (Institut de l'Information Scientifique et Technique)
Yashiro, M., Qiu, H., Hasegawa, T., Zhang, X., Morisaki, T., Fukuoka, T., Aomatsu, N., Hirakawa, T., Sakurai, K., Kubo, N., et al. (2012) · Cancer Research · doi:10.1158/1538-7445.am2012-780
Evolution of cancer cell resistance versus intelligent design of epigenetic drugs
Barbieri, I., & Bannister, A. J. (2014) · Drug Discovery Today Disease Models · doi:10.1016/j.ddmod.2014.05.005
Temmink, O. H. (2007) · Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam)
Lipid mediators in the prevention and therapy of neuroblastoma
Gleissman, H. (2009) · Figshare · Cited by 1
Predictive factors in esophageal carcinoma.
Dreilich, M. (2006) · KTH Publication Database DiVA (KTH Royal Institute of Technology)
Astrocyte elevated gene-1 in relation to colorectal cancer development and radiotherapy response
Gnosa, S. P. (2015) · Linköping University medical dissertations · doi:10.3384/diss.diva-121868
Targeted Therapies For Intestinal Tumorigenesis
Chiorean, E. G., Coveler, A. L., Grim, J. E., & Grady, W. M. (2015) · Springer eBooks · doi:10.1007/978-3-319-19986-3_13
UNIVERSITAT DE BARCELONA DIVISIÓ DE CIÈNCIES DE LA SALUT
de Medicina, F. (2003)
Logan, R. M. (2008) · Adelaide Research & Scholarship (AR&S) (University of Adelaide)
Adjuvant Treatment in Colon Cancer
Donev, I. S., Kolev, N. Y., Ignatov, V., Tonev, A. Y., Zlatarov, A. K., Konsoulova, A., Entcheva, E., Drenakova, P., & Ivanov, K. D. (2016) · InTech eBooks · doi:10.5772/64101
Chernov, A. (2016) · cIRcle (University of British Columbia) · doi:10.14288/1.0306412
Research of irinotecan stability in different methods of active loading into liposomes
Стадниченко, А. В., Краснопольский, Ю. М., Швец, В. И., & Ярных, Т. Г. (2016) · ScienceRise Pharmaceutical Science · doi:10.15587/2519-4852.2016.74454
Regulska, K., Stanisz, B. J., & Gieremek, P. (2014)
Attenuated apoptosis as consequence of Epithelial Mesenchymal Transition
Keitel, U. (2014) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-4648
Determination of liposome internal volume with irinotekan
Стадниченко, А. В., Krasnopolskyi, Y. M., Швец, В. И., & Yarnykh, Т. G. (2016) · Ukrainian biopharmaceutical journal · doi:10.24959/ubphj.16.72
Al-Masud, A. A. (2017) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r3s756x6s
STUDY OF JADOMYCIN PHARMACOKINETICS AND ANTI-BREAST CANCER ACTIVITY IN BALB/C MICE
Relja, N. J. (2019) · DalSpace (Dalhousie University)
Issues in Laboratory Animal Science That Impact Toxicologic Pathology
Everitt, J. I., King-Herbert, A. P., Clements, P., & Adler, R. R. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821044-4.00006-6
Huang, C., Pai, Y.-C., & Yu, L. C. (2021) · Research Square · doi:10.21203/rs.3.rs-1175570/v1
Lipp, H., Hartmann, J. T., & Stanley, A. (2004) · Side effects of drugs annual · doi:10.1016/s0378-6080(04)80052-7
(2006) · Elsevier eBooks · doi:10.1016/b0-44-451005-2/01052-4
SIC50: Determination of IC50 by an optimized Sobel operator and a vision transformerPreprint
Wang, Y., Zhang, W., Yip, H., Qu, C., Hu, H., Chen, X., Lee, T., Yang, X., Yang, B., Kumar, P., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.08.12.503661
Data from Targeting the p38 MAPK Pathway Inhibits Irinotecan Resistance in Colon Adenocarcinoma
Paillas, S., Boissière‐Michot, F., Bibeau, F., Denouël, A., Mollévi, C., Causse, A., Denis, V., Vié, N., Marzi, L., Cortijo, C., et al. (2023) · doi:10.1158/0008-5472.c.6502749
Data from Targeting the p38 MAPK Pathway Inhibits Irinotecan Resistance in Colon Adenocarcinoma
Paillas, S., Boissière‐Michot, F., Bibeau, F., Denouël, A., Mollévi, C., Causse, A., Denis, V., Vié, N., Marzi, L., Cortijo, C., et al. (2023) · doi:10.1158/0008-5472.c.6502749.v1
Dopeso, H., Mateo‐Lozano, S., Élez, E., Landolfi, S., Ramos, F. J., Hernández‐Losa, J., Mazzolini, R., Rodrigues, P., Bazzocco, S., Carreras, M. J., et al. (2023) · doi:10.1158/1078-0432.c.6519096.v1
Dopeso, H., Mateo‐Lozano, S., Élez, E., Landolfi, S., Ramos, F. J., Hernández‐Losa, J., Mazzolini, R., Rodrigues, P., Bazzocco, S., Carreras, M. J., et al. (2023) · doi:10.1158/1078-0432.c.6519096
Dopeso, H., Mateo‐Lozano, S., Élez, E., Landolfi, S., Ramos, F. J., Hernández‐Losa, J., Mazzolini, R., Rodrigues, P., Bazzocco, S., Carreras, M. J., et al. (2023) · doi:10.1158/1078-0432.22442343
Cecchini, M., Walther, Z., Wei, W., Hafez, N., Pilat, M. J., Boerner, S. A., Durecki, D. E., Eder, J. P., Schalper, K. A., Chen, A. P., et al. (2023) · doi:10.1158/2767-9764.23391245.v1
Cecchini, M., Walther, Z., Wei, W., Hafez, N., Pilat, M. J., Boerner, S. A., Durecki, D. E., Eder, J. P., Schalper, K. A., Chen, A. P., et al. (2023) · doi:10.1158/2767-9764.23579961.v1
Cecchini, M., Walther, Z., Wei, W., Hafez, N., Pilat, M. J., Boerner, S. A., Durecki, D. E., Eder, J. P., Schalper, K. A., Chen, A. P., et al. (2023) · doi:10.1158/2767-9764.23579961
King, J. J., Mowla, A., Kretzmann, J. A., Nörret, M., Kadolsky, U. D., Iqbal, M. M., Saxena, A., Mamsa, S. S. A., Amos, S. E., Choi, Y. S., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.11.20.567985
Wright, C., Gordon, E. R., & Cooper, S. J. (2023) · Figshare · doi:10.6084/m9.figshare.24630276
Investigations of the effects of coffee in chemotherapy
Kalthoff, S., & Strassburg, C. P. (2024) · Coffee in Health and Disease Prevention · doi:10.1016/b978-0-443-13868-3.00008-9
The Possibility of DNA Methylation for Precision Medicine in Colorectal Cancer
Sugimoto, K. (2025) · Juntendō Igaku/Juntendo igaku · doi:10.14789/ejmj.jmj25-0002-r
Elmarrachi, H., Andrif, M., & Ismaili, N. (2025) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2025.100974
Zeng, C., Ufere, N. N., Dykes, P. C., Zhai, S., Chen, Y.-J., Ye, J., Edelen, M. O., Pusic, A. L., Liu, J. B., Lau‐Min, K. S., et al. (2025) · medRxiv · doi:10.1101/2025.10.08.25337569
Dilber, T., Yalçın, G. D., Yilmaz, K. C., & Acar, A. (2025) · FEBS Letters · doi:10.1002/1873-3468.70208
Paulishak, W., Lyu, J., VanNieuwenhze, M. S., & Wood, L. M. (2025) · Cell chemical biology · doi:10.1016/j.chembiol.2025.11.008
Wu, X., Li, L., Zhan, Z., Chang, M., Li, J., Chen, Z., & Wang, Z. (2025) · PLoS ONE · doi:10.1371/journal.pone.0337731
Yuan, M., Chen, T., Jin, L., Zhang, P., Xie, L., Zhou, S., Fan, L., Wang, L., Zhang, C., Tang, N., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24454968
Wright, C. A., Gordon, E. R., & Cooper, S. J. (2024) · Figshare · doi:10.6084/m9.figshare.26644360
Wright, C. A., Gordon, E. R., & Cooper, S. J. (2024) · Figshare · doi:10.6084/m9.figshare.26644354
Wright, C. A., Gordon, E. R., & Cooper, S. J. (2024) · Figshare · doi:10.6084/m9.figshare.26644351
Wright, C. A., Gordon, E. R., & Cooper, S. J. (2024) · Figshare · doi:10.6084/m9.figshare.26644348
Wright, C. A., Gordon, E. R., & Cooper, S. J. (2024) · Figshare · doi:10.6084/m9.figshare.24630430
Wright, C. A., Gordon, E. R., & Cooper, S. J. (2024) · Figshare · doi:10.6084/m9.figshare.26644342
Wright, C. A., Gordon, E. R., & Cooper, S. J. (2024) · Figshare · doi:10.6084/m9.figshare.26644357
Wright, C. A., Gordon, E. R., & Cooper, S. J. (2024) · Figshare · doi:10.6084/m9.figshare.26644345
Nagi, R., Ozukum, A., Mondal, R., & Deb, C. R. (2026) · Journal of Experimental Biology and Agricultural Sciences · doi:10.18006/2026.14(1).44.54
Benzylisoquinoline alkaloid dimers with antitumor activities from Thalictrum wangii B. Boivin
Jin, Q., Liu, X.-M., Liu, D.-M., Shi, X., Yang, Q., Zhao, Y.-L., Zhao, L., Dai, Z., & Luo, X. (2026) · Phytochemistry · doi:10.1016/j.phytochem.2026.114856
Paillas, S. (2011) · theses.fr (ABES) · doi:10.70675/185485eez159ez4fcaza3fcz8da97d26c77f
Les plasmas froids, nouvelle stratégie thérapeutique en cancérologie
Vandamme, M. (2012) · theses.fr (ABES) · doi:10.70675/6c208bb1zfa66z4b33z8b69z39f1f07a523f · Cited by 6
Metadata
- Authors
- Xu, Y., & Villalona-Calero, M. A.
- Affiliations
- The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
- Corresponding author
- Villalona-Calero, M.A.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2002-12
- Volume
- 13
- Issue
- 12
- Pages
- 1841-1851
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2112055293
- Cited by
- 413
- References
- 124
- Citations by year
- 2026: 25 · 2025: 18 · 2024: 25 · 2023: 40 · 2022: 30 · 2021: 23 · 2020: 24 · 2019: 17 · 2018: 16 · 2017: 22 · 2016: 15 · 2015: 24 · 2014: 13 · 2013: 11 · 2012: 10
- FWCI
- 0.55
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 6246 d)
- Locations
- Annals of Oncology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Texas Health Science Center at San Antonio
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
- Keywords
- irinotecan, camptothecin, topoisomerase I, drug resistance, drug efflux, proteasomal degradation, DNA repair, NF-κB, apoptosis, anticancer drug metabolism, combination therapy
- MeSH terms
- Irinotecan, Animals, Camptothecin, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Humans, Male, Neoplasms, Sensitivity and Specificity, NF-kappa B, Apoptosis, Risk Assessment, Drug Resistance, Neoplasm, Maximum Tolerated Dose, Topoisomerase I Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.